首页> 外文期刊>Journal of Cardiovascular Translational Research >Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome
【24h】

Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome

机译:抗血小板治疗在急性冠脉综合征二级预防中的作用

获取原文
获取原文并翻译 | 示例
           

摘要

Cardiovascular disease is one of the major causes of death in developed countries, mainly related to coronary artery disease and its acute complications. Platelets play a great role in the pathogenesis of acute thrombotic events of coronary artery disease when silent chronic disease becomes acutely symptomatic. Platelet importance in coronary artery disease and pathophysiology of acute events support the large benefit of antiplatelet agents for both acute management of ACS and secondary prevention. Recent developments in oral antiplatelet therapy raised questions about the choice of the molecules, the use of single or double therapy, and the optimal dosing and duration of treatment. The present review aims to provide a current appraisal of antiplatelet therapy use after ACS and to summarize available scientific evidence for an optimal use of antiplatelet agents in daily practice, including the new P2Y12 blockers.
机译:心血管疾病是发达国家的主要死亡原因之一,主要与冠状动脉疾病及其急性并发症有关。当无症状的慢性疾病成为急性症状时,血小板在冠状动脉疾病的急性血栓形成事件的发病机理中起重要作用。血小板在冠状动脉疾病和急性事件的病理生理中的重要性支持了抗血小板药物对ACS的急性治疗和二级预防的巨大益处。口服抗血小板治疗的最新发展提出了有关分子选择,单药或双药治疗以及最佳剂量和治疗持续时间的问题。本综述旨在提供ACS后抗血小板治疗的当前评估,并总结在日常实践中最佳使用抗血小板药物(包括新型P2Y12阻滞剂)的现有科学证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号